Lilly and Evotec enter partnership for metabolic disease drug discovery
Evotec will receive undisclosed upfront, milestone and tiered royalty payments totalling up to $1bn.
Metabolic Disorders
Latest in
Metabolic Disorders
Knowledge of effects of severe anorexia can inspire patients to seek assistance
To avoid the life-threatening consequences of anorexia, it is important patients can access treatment at the earliest opportunity.
By
FDA approves Sanofi’s Nexviazyme for Pompe disease treatment
The enzyme replacement therapy can enhance the uptake of cellular enzymes and boost glycogen clearance in target muscle cells.
Takeda sells Japan’s non-core products portfolio to Teijin Pharma
Takeda Pharmaceutical has completed the asset transfer linked to a portfolio of select non-core products in Japan to Teijin Pharma…
Takeda to sell diabetes products portfolio to Teijin Pharma for $1.25bn
Takeda Pharmaceutical Company has signed an agreement to sell four non-core type 2 diabetes products in Japan to Teijin Pharma…
Takeda to divest non-core assets to Hasten Biopharmaceutic for $322m
Takeda Pharmaceutical Company has signed an agreement to divest a portfolio of five non-core prescription pharmaceutical assets sold in China…
Calliditas takes control of Genkyotex: expanding the rare disease pipeline
Calliditas has acquired the controlling interest, 62.7%, of Genkyotex for €19.8m. This deal expands Calliditas’s rare disease pipeline, which centres…
By
Neutralising the gluten threat: are we on the cusp of a coeliac disease breakthrough?
Different from a gluten intolerance, coeliac disease causes long-term damage to patients’ small intestine and puts them at risk of…
By